U.S. drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc , paying $1.25 billion ...

Pfizer will pay $1.25 billion upfront to license an experimental cancer drug out of China, in a deal that underscores ...

Pfizer jumps into cancer-treatment race with a $6 billion licensing deal with a China-based company, six months after Merck’s ...

Pfizer Inc. has secured an exclusive global licensing agreement with 3SBio, Inc., a leading Chinese biopharma, for SSGJ-707.

Pfizer’s top cancer drugs are small molecules ... Furthermore, the big pharma has committed to a $100 million equity investment in 3SBio. The 3SBio drug, SSGJ-707, treats cancer by blocking ...

Pfizer will pay China’s 3SBio $1.25 billion up front to access a cancer drug that could rival Akeso and Summit’s closely ...

Pfizer Inc. announced Monday it has secured exclusive global rights, excluding China, to 3SBio Inc.'s bispecific antibody ...

Pfizer (NYSE:PFE) has signed an exclusive global licensing deal with China’s 3SBio for the development of its cancer drug candidate ... will make a $100M equity investment in 3SBio subject ...

The deal comes three months after Pfizer inked a PD-1/VEGF partnership with Summit Therapeutics, leading BMO Capital Markets ...

Pfizer-backed CellCentric has secured $120 million in series C funds as the British biotech prepares to take its multiple ...

(Reuters) -U.S. drugmaker Pfizer said it would ... The licensed drug candidate, SSGJ-707, is being evaluated for non-small cell lung cancer, metastatic colorectal cancer and gynaecological tumors.

NEW YORK - Pfizer Inc. (NYSE:PFE), a pharmaceutical giant with $62.46 billion in revenue and a market capitalization of $130.76 billion, has secured an exclusive licensing agreement with Chinese ...